Home Healthcare Biotechnology Oncolytic Virus Therapies Market

Oncolytic Virus Therapies Market Size, Share & Trends Analysis Report By Commercialized Therapies (Imlygic, Oncorine, RIGVIR), By Pipeline Therapies (Phase I, Phase II, Phase III, Phase IV), By Type of Virus (Genetically Engineered Oncolytic Virus, Reovirus (Respiratory Enteric Orphan Virus)), By Application (Solid Tumor, Hematological Malignancies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Debashree B | Format: | Report Code: SR3480DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Table Of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. Oncolytic Virus Therapies Market Size Analysis
    1. Introduction
    2. Oncolytic Virus Therapies Market Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
      1. Imlygic
      2. Oncorine
      3. RIGVIR
    3. Oncolytic Virus Therapies Market Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
      1. Phase I
      2. Phase II
      3. Phase III
      4. Phase IV
    4. Oncolytic Virus Therapies Market Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
      1. Genetically Engineered Oncolytic Virus
        1. Herpes Simplex Virus (HSV)
        2. Adenovirus
        3. Vaccinia Virus
        4. Oncolytic Wild-Type Virus
      2. Reovirus (Respiratory Enteric Orphan Virus)
        1. Newcastle Disease Virus (NDV)
        2. Vesicolar Stomatitis Virus (VSV)
    5. Oncolytic Virus Therapies Market Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
      1. Solid Tumor
        1. Breast Cancer
        2. Prostate Cancer
        3. Lung Cancer
        4. Glioblastoma
        5. Melanoma
        6. Other Applications
      2. Hematological Malignancies
        1. Lymphoma
        2. Leukemia
        3. Myeloma
  7. North America Oncolytic Virus Therapies Market Size Analysis
    1. Introduction
    2. Oncolytic Virus Therapies Market Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
      1. Imlygic
      2. Oncorine
      3. RIGVIR
    3. Oncolytic Virus Therapies Market Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
      1. Phase I
      2. Phase II
      3. Phase III
      4. Phase IV
    4. Oncolytic Virus Therapies Market Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
      1. Genetically Engineered Oncolytic Virus
        1. Herpes Simplex Virus (HSV)
        2. Adenovirus
        3. Vaccinia Virus
        4. Oncolytic Wild-Type Virus
      2. Reovirus (Respiratory Enteric Orphan Virus)
        1. Newcastle Disease Virus (NDV)
        2. Vesicolar Stomatitis Virus (VSV)
    5. Oncolytic Virus Therapies Market Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
      1. Solid Tumor
        1. Breast Cancer
        2. Prostate Cancer
        3. Lung Cancer
        4. Glioblastoma
        5. Melanoma
        6. Other Applications
      2. Hematological Malignancies
        1. Lymphoma
        2. Leukemia
        3. Myeloma
    6. U.S.
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    7. Canada
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
  8. Europe Oncolytic Virus Therapies Market Size Analysis
    1. Introduction
    2. Oncolytic Virus Therapies Market Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
      1. Imlygic
      2. Oncorine
      3. RIGVIR
    3. Oncolytic Virus Therapies Market Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
      1. Phase I
      2. Phase II
      3. Phase III
      4. Phase IV
    4. Oncolytic Virus Therapies Market Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
      1. Genetically Engineered Oncolytic Virus
        1. Herpes Simplex Virus (HSV)
        2. Adenovirus
        3. Vaccinia Virus
        4. Oncolytic Wild-Type Virus
      2. Reovirus (Respiratory Enteric Orphan Virus)
        1. Newcastle Disease Virus (NDV)
        2. Vesicolar Stomatitis Virus (VSV)
    5. Oncolytic Virus Therapies Market Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
      1. Solid Tumor
        1. Breast Cancer
        2. Prostate Cancer
        3. Lung Cancer
        4. Glioblastoma
        5. Melanoma
        6. Other Applications
      2. Hematological Malignancies
        1. Lymphoma
        2. Leukemia
        3. Myeloma
    6. U.K.
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    7. Germany
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    8. France
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    9. Spain
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    10. Italy
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    11. Russia
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    12. Nordic
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    13. Benelux
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    14. Rest of Europe
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
  9. APAC Oncolytic Virus Therapies Market Size Analysis
    1. Introduction
    2. Oncolytic Virus Therapies Market Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
      1. Imlygic
      2. Oncorine
      3. RIGVIR
    3. Oncolytic Virus Therapies Market Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
      1. Phase I
      2. Phase II
      3. Phase III
      4. Phase IV
    4. Oncolytic Virus Therapies Market Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
      1. Genetically Engineered Oncolytic Virus
        1. Herpes Simplex Virus (HSV)
        2. Adenovirus
        3. Vaccinia Virus
        4. Oncolytic Wild-Type Virus
      2. Reovirus (Respiratory Enteric Orphan Virus)
        1. Newcastle Disease Virus (NDV)
        2. Vesicolar Stomatitis Virus (VSV)
    5. Oncolytic Virus Therapies Market Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
      1. Solid Tumor
        1. Breast Cancer
        2. Prostate Cancer
        3. Lung Cancer
        4. Glioblastoma
        5. Melanoma
        6. Other Applications
      2. Hematological Malignancies
        1. Lymphoma
        2. Leukemia
        3. Myeloma
    6. China
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    7. Korea
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    8. Japan
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    9. India
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    10. Australia
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    11. Taiwan
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    12. South East Asia
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    13. Rest of Asia-Pacific
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
  10. Middle East and Africa Oncolytic Virus Therapies Market Size Analysis
    1. Introduction
    2. Oncolytic Virus Therapies Market Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
      1. Imlygic
      2. Oncorine
      3. RIGVIR
    3. Oncolytic Virus Therapies Market Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
      1. Phase I
      2. Phase II
      3. Phase III
      4. Phase IV
    4. Oncolytic Virus Therapies Market Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
      1. Genetically Engineered Oncolytic Virus
        1. Herpes Simplex Virus (HSV)
        2. Adenovirus
        3. Vaccinia Virus
        4. Oncolytic Wild-Type Virus
      2. Reovirus (Respiratory Enteric Orphan Virus)
        1. Newcastle Disease Virus (NDV)
        2. Vesicolar Stomatitis Virus (VSV)
    5. Oncolytic Virus Therapies Market Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
      1. Solid Tumor
        1. Breast Cancer
        2. Prostate Cancer
        3. Lung Cancer
        4. Glioblastoma
        5. Melanoma
        6. Other Applications
      2. Hematological Malignancies
        1. Lymphoma
        2. Leukemia
        3. Myeloma
    6. UAE
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    7. Turkey
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    8. Saudi Arabia
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    9. South Africa
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    10. Egypt
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    11. Nigeria
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    12. Rest of MEA
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
  11. LATAM Oncolytic Virus Therapies Market Size Analysis
    1. Introduction
    2. Oncolytic Virus Therapies Market Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
      1. Imlygic
      2. Oncorine
      3. RIGVIR
    3. Oncolytic Virus Therapies Market Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
      1. Phase I
      2. Phase II
      3. Phase III
      4. Phase IV
    4. Oncolytic Virus Therapies Market Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
      1. Genetically Engineered Oncolytic Virus
        1. Herpes Simplex Virus (HSV)
        2. Adenovirus
        3. Vaccinia Virus
        4. Oncolytic Wild-Type Virus
      2. Reovirus (Respiratory Enteric Orphan Virus)
        1. Newcastle Disease Virus (NDV)
        2. Vesicolar Stomatitis Virus (VSV)
    5. Oncolytic Virus Therapies Market Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
      1. Solid Tumor
        1. Breast Cancer
        2. Prostate Cancer
        3. Lung Cancer
        4. Glioblastoma
        5. Melanoma
        6. Other Applications
      2. Hematological Malignancies
        1. Lymphoma
        2. Leukemia
        3. Myeloma
    6. Brazil
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    7. Mexico
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    8. Argentina
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    9. Chile
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    10. Colombia
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
    11. Rest of LATAM
      1. Introduction
      2. Market Size & Forecast By Commercialized Therapies 2022-2034 (USD MILLION/ Units)
        1. Imlygic
        2. Oncorine
        3. RIGVIR
      3. Market Size & Forecast By Pipeline Therapies 2022-2034 (USD MILLION/ Units)
        1. Phase I
        2. Phase II
        3. Phase III
        4. Phase IV
      4. Market Size & Forecast By Type of Virus 2022-2034 (USD MILLION/ Units)
        1. Genetically Engineered Oncolytic Virus
          1. Herpes Simplex Virus (HSV)
          2. Adenovirus
          3. Vaccinia Virus
          4. Oncolytic Wild-Type Virus
        2. Reovirus (Respiratory Enteric Orphan Virus)
          1. Newcastle Disease Virus (NDV)
          2. Vesicolar Stomatitis Virus (VSV)
      5. Market Size & Forecast By Application 2022-2034 (USD MILLION/ Units)
        1. Solid Tumor
          1. Breast Cancer
          2. Prostate Cancer
          3. Lung Cancer
          4. Glioblastoma
          5. Melanoma
          6. Other Applications
        2. Hematological Malignancies
          1. Lymphoma
          2. Leukemia
          3. Myeloma
  12. Competitive Landscape
    1. Oncolytic Virus Therapies Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    3. Tier Structure Analysis
    4. Recent Developments
  13. Market Players Assessment
    1. Amgen Inc
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. DAIICHI SANKYO COMPANY LIMITED
    3. DNAtrix
    4. Genelux
    5. Oncolytics Biotech Inc
    6. PsiOxus Therapeutics
    7. RIGVIR Ltd
    8. Shanghai Sunway Biotech Co. Ltd.
    9. SillaJen Inc
    10. Sorrento Therapeutics Inc
    11. Takara Bio Inc
    12. Transgene SA
    13. VCNBiosciences
    14. ViroCure
    15. Viralytics Ltd.(Merck & Co., Inc.) 
  14. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data from Secondary Sources
      2. Primary Data
        1. Key Data from Primary Sources
        2. Breakdown of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  15. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  16. Disclaimer
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.